Jos Jonkers Selected Research

Lobular Carcinoma

10/2021	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.
1/2020	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.
1/2019	Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin.
12/2016	p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice.
1/2016	PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.
4/2015	Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase.
5/2013	Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.
8/2011	Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.
5/2011	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.
3/2009	Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jos Jonkers Research Topics

Disease

127	Neoplasms (Cancer) 01/2022 - 03/2002
70	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2004
11	Lobular Carcinoma 10/2021 - 11/2006
11	Carcinoma (Carcinomatosis) 01/2018 - 08/2004
11	Carcinogenesis 01/2018 - 03/2002
9	Neoplasm Metastasis (Metastasis) 01/2020 - 07/2006
5	Triple Negative Breast Neoplasms 01/2020 - 12/2009
4	Genomic Instability 12/2021 - 11/2010
4	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 01/2012
4	Hypersensitivity (Allergy) 10/2017 - 06/2010
3	Retinoblastoma (Glioblastoma, Retinal) 01/2020 - 03/2002
2	Fanconi Anemia (Fanconi's Anemia) 07/2021 - 03/2021
2	Inflammation (Inflammations) 03/2021 - 01/2019
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2019
2	Hypoxia (Hypoxemia) 04/2020 - 10/2017
2	Stomach Neoplasms (Stomach Cancer) 03/2013 - 03/2012
2	Aneuploidy (Aneuploid) 04/2007 - 01/2004
1	COVID-19 03/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2021
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2020
1	Endometrial Neoplasms (Endometrial Cancer) 12/2019
1	Respiratory Syncytial Virus Infections 01/2019
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2019
1	Bites and Stings (Sting) 01/2019

Drug/Important Bio-Agent (IBA)

29	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 06/2008
25	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2004
21	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2008
19	Pharmaceutical PreparationsIBA 01/2022 - 11/2007
18	Cadherins (E-Cadherin)IBA 01/2020 - 11/2006
15	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 07/2007
14	olaparibIBA 04/2020 - 06/2008
14	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020 - 11/2008
13	PlatinumIBA 07/2021 - 11/2008
8	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2010
6	Estrogen ReceptorsIBA 10/2021 - 07/2007
5	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2019 - 09/2008
5	Docetaxel (Taxotere)FDA Link 01/2018 - 07/2007
5	Hormones (Hormone)IBA 01/2018 - 11/2008
5	Alkylating AgentsIBA 11/2017 - 01/2010
5	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 10/2016 - 08/2009
4	Biological ProductsIBA 10/2021 - 02/2008
4	LigandsIBA 01/2019 - 01/2016
4	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2018
4	Estrogens (Estrogen)FDA Link 01/2018 - 09/2008
4	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2015 - 07/2007
3	ChromatinIBA 07/2021 - 01/2017
3	Platinum Compounds (Compounds, Platinum)IBA 07/2021 - 09/2008
3	BRCA1 ProteinIBA 01/2021 - 01/2016
3	Transcription Factors (Transcription Factor)IBA 01/2020 - 08/2017
3	ActomyosinIBA 01/2020 - 01/2018
3	Topoisomerase I InhibitorsIBA 01/2020 - 02/2010
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 01/2019 - 02/2010
3	NimustineIBA 11/2017 - 01/2010
3	Delta CateninIBA 12/2016 - 08/2011
3	ProteomeIBA 09/2016 - 07/2012
3	Messenger RNA (mRNA)IBA 01/2016 - 08/2004
3	CytokinesIBA 08/2013 - 05/2006
2	Phosphotransferases (Kinase)IBA 01/2022 - 04/2015
2	GSK-2816126IBA 01/2022 - 01/2019
2	Poly Adenosine Diphosphate RiboseIBA 11/2021 - 11/2018
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2012
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2019 - 08/2017
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2018 - 09/2008
2	CateninsIBA 01/2018 - 03/2013
2	Melphalan (Alkeran)FDA LinkGeneric 11/2016 - 01/2010
2	Cell Adhesion MoleculesIBA 01/2016 - 10/2008
2	SaltsIBA 05/2014 - 01/2012
2	Peptides (Polypeptides)IBA 01/2013 - 08/2009
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 08/2012 - 08/2009
2	Phenobarbital (Luminal)FDA Link 06/2012 - 11/2010
2	Topotecan (Hycamtin)FDA LinkGeneric 01/2012 - 02/2010
2	LuciferasesIBA 12/2010 - 03/2002
2	Small Interfering RNA (siRNA)IBA 01/2010 - 08/2009
2	Antineoplastic Agents (Antineoplastics)IBA 01/2009 - 03/2002
1	SiliconIBA 01/2022
1	AZD1390IBA 01/2022
1	apalutamideIBA 01/2022
1	Drug CombinationsIBA 01/2022
1	EnzymesIBA 07/2021
1	CX3C Chemokine Receptor 1IBA 03/2021
1	Chemokine ReceptorsIBA 03/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	GlucocorticoidsIBA 01/2021
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2021
1	CytidineIBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	CamptothecinIBA 01/2020
1	Co-Repressor ProteinsIBA 01/2020
1	indimitecanIBA 01/2020
1	berzosertibIBA 01/2020
1	NSC 724998IBA 01/2020
1	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 01/2020
1	GATA3 Transcription FactorIBA 01/2019

Therapy/Procedure

45	Therapeutics 01/2022 - 03/2002
19	Drug Therapy (Chemotherapy) 12/2021 - 07/2007
7	Transplantation 12/2010 - 09/2007
4	Radiotherapy 01/2020 - 10/2017
3	Precision Medicine 01/2018 - 01/2017
2	Mastectomy (Mammectomy) 01/2019 - 01/2013
2	Ovariectomy (Oophorectomy) 01/2018 - 08/2012